Need a Good Dentist? You Might Want to Head to Mexico
Can you say “dentista?”
Increasingly expensive dental care costs are forcing seniors to bite down hard—and head to Mexico to preserve their pearly whites, the Associated Press reports.
Nearly 70 percent of seniors do not have dental insurance, according to a 2013 Harris Interactive survey commissioned by Oral Health America. Medicare does not cover dental care, and many employers do not offer post-retirement health benefits. You can get dental coverage through the Affordable Care Act, but only if you purchase general health coverage first. (Many seniors already have that coverage.)
Even with coverage, crowns, bridgework, implants and dental surgery can easily exceed the annual limit. As a result, seniors who need extensive dental work may have limited options and could face out-of-pocket costs running into the thousands or tens of thousands of dollars; 23 percent of seniors in the Oral Health America survey said they have not seen a dental provider in five years.
Related: The Hidden Costs of Dental Neglect
Just as people traveled to Canada to buy their prescription drugs at lower cost or traveling the world for other medical services and procedures, more Americans are now flocking to places like Los Algodones, Mexico for dental care. Dental care in Mexico is much cheaper, thanks to lower labor costs and fewer regulatory requirements — factors that you should keep in mind before heading south of the border. The dentists in Mexico maintain that they may not have as much education as their American counterparts, but they spend more time practicing clinical work.
It’s not just people who live in border cities like El Paso, Texas crossing the border to take care of their teeth. The Associated Press reports that shuttle services exist to take dental patients from the Phoenix area to Los Algodones, a 200-mile trip.
Before you book a trip, though, remember that should something go wrong you may not have the same legal recourse as in the U.S., and the dentists may use different types of equipment--so do your research first.
Top Reads from The Fiscal Times:
- America’s 10 Top Selling Medications
- Medicare’s Bold New Move on Knee and Hip Replacements
- 9 Social Security Tips You Need to Know Right Now
Chart of the Day: High Deductible Blues
The higher the deductible in your health insurance plan, the less happy you probably are with it. That’s according to a new report on employer-sponsored health insurance from the Kaiser Family Foundation and the Los Angeles Times.
Chart of the Day: Tax Cuts and the Missing Capex Boom
Despite the Republican tax overhaul, businesses aren’t significantly increasing their capital expenditures. “The federal government will have to borrow an added $1 trillion through 2027 to pay for the corporate tax breaks,” says Bloomberg’s Mark Whitehouse. “So far, it’s hard to see what the country is getting in return.”
Chart of the Day: 2019’s Lobbying Leaders
Roll Call reports that trade, infrastructure and health care issues including prescription drug prices “dominated the lobbying agendas of some of the biggest spenders on K Street early this year.” Here’s Roll Call’s look at the top lobbying spenders so far this year:
Can You Fix Social Security? A New Tool Lets You Try
The Congressional Budget Office released an interactive tool Wednesday that shows how some widely discussed policy changes would affect the long-run financial health of the Social Security system.
“This interactive tool allows the user to explore seven policy options that could be used to improve the Social Security program’s finances and delay the trust funds’ exhaustion,” CBO said. “Four options would reduce benefits, and three options would increase payroll taxes. The tool allows for any combination of those options. It also lets the user change implementation dates and choose whether to show scheduled or payable benefits. … The tool also shows the impact of the options on different groups of people.”
Click here to view the interactive tool on the CBO website.
Why Prescription Drug Prices Keep Rising – and 3 Ways to Bring Them Down
Prescription drug prices have been rising at a blistering rate over the last few decades. Between 1980 and 2016, overall spending on prescription drugs rose from about $12 billion to roughly $330 billion, while its share of total health care spending doubled, from 5% to 10%.
Although lawmakers have shown renewed interest in addressing the problem, with pharmaceutical CEOs testifying before the Senate Finance Committee in February and pharmacy benefit managers (PBMS) scheduled to do so this week, no comprehensive plan to halt the relentless increase in prices has been proposed, let alone agreed upon.
Robin Feldman, a professor at the University of California Hastings College of Law, takes a look at the drug pricing system in a new book, “Drugs, Money and Secret Handshakes: The Unstoppable Growth of Prescription Drug Prices.” In a recent conversation with Bloomberg’s Joe Nocera, Feldman said that one of the key drivers of rising prices is the ongoing effort of pharmaceutical companies to maintain control of the market.
Fearing competition from lower-cost generics, drugmakers began over the last 10 or 15 years to focus on innovations “outside of the lab,” Feldman said. These innovations include paying PBMs to reduce competition from generics; creating complex systems of rebates to PBMs, hospitals and doctors to maintain high prices; and gaming the patent system to extend monopoly pricing power.
Feldman’s research on the dynamics of the drug market led her to formulate three general solutions for the problem of ever-rising prices:
1) Transparency: The current system thrives on secret deals between drug companies and middlemen. Transparency “lets competitors figure out how to compete and it lets regulators see where the bad behaviors occur,” Feldman says.
2) Patent limitations: Drugmakers have become experts at extending patents on existing drugs, often by making minor modifications in formulation, dosage or delivery. Feldman says that 78% of drugs getting new patents are actually old drugs gaining another round of protection, and thus another round of production and pricing exclusivity. A “one-and-done” patent system would eliminate this increasingly common strategy.
3) Simplification: Feldman says that “complexity breeds opportunity,” and warns that the U.S. “drug price system is so complex that the gaming opportunities are endless.” While “ruthless simplification” of regulatory rules and approval systems could help eliminate some of those opportunities, Feldman says that the U.S. doesn’t seem to be moving in this direction.
Read the full interview at Bloomberg News.